Loading…
India's largest pharmaceutical contract manufacturer (CDMO), making formulations for other drug companies plus its own generics.
India's largest pharmaceutical contract manufacturer (CDMO), making formulations for other drug companies plus its own generics.
Makes formulations, finished tablets, injections and softgels, to the specifications of other drug companies, which sell them under their own labels, so income is contract-manufacturing fees spread across many customers rather than one product. It listed on the stock market in 2024.
Moat: narrow (scale, regulatory licence, process know-how). Largest-scale, multi-approval manufacturing base in India's CDMO market, though the space has several capable rivals.
Headquarters: Haridwar, India · Founded: 2004 · Employees: 18,010
Size Akums Drugs and Pharmaceuticals (AKUMS.NS) is an India Health Care company (Biotechnology) with a market value of $1.22B, the 542nd largest of 1,058 India companies the cockpit tracks. Shares closed at ₹734.95 on 6 Nov 2026.
Performance Over six months the shares gained 34.1%, against -15.8% for the median peer and 0.0% for the India market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 17.5% over the last twelve months (peer median -4.6%); the operating margin is 10.4% (peer median -81.3%).
Valuation It trades at 27.0× forward earnings against a peer median of 30.2× (3rd cheapest of 7).
Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.6 points above its cost of capital (13.4% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹48.3B | ₹43.6B | ₹41.2B | ₹41.8B | ₹36.5B |
| Revenue growth | — | +6% | -1% | +14% | — |
| Gross profit | ₹11.0B | ₹6.85B | ₹5.91B | ₹6.27B | ₹4.57B |
| EBITDA | ₹6.68B | ₹5.26B | ₹4.63B | ₹4.85B | ₹3.09B |
| Net income | ₹3.64B | ₹2.55B | ₹3.38B | -₹40.4M | ₹949M |
| Free cash flow | n/a | ₹9.80B | ₹1.90B | ₹1.55B | -₹1.85B |
| Capital expenditure | n/a | ₹2.31B | ₹2.72B | ₹3.11B | ₹3.29B |
| Total debt | ₹1.17B | ₹1.57B | ₹882M | ₹5.65B | ₹6.19B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals AKUMS.NS | $1.22B | +34% | +18% | 10% | 27.0× | 15.8% |
| Divi's Laboratories DIVISLAB.NS | $29.0B | +54% | +16% | 31% | 82.0× | 50.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AKUMS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.7% | -3.5% | 8th lowest of 21 |
| 6-month return | +34.1% | -15.8% | 4th highest of 20 |
| Distance from 52-week high | -12.4% | -43.6% | 2nd highest of 21 |
| Revenue growth (TTM) | +17.5% | -4.6% | 5th highest of 14 |
| Operating margin | 10.4% | -81.3% | 2nd highest of 14 |
| Forward P/E | 27.0× | 30.2× | 3rd cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | 15.8% | 8.8% | 3rd most demanding of 6 |
| Growth delivered (Del g) | +9.9% | -7.0% | 2nd highest of 6 |
| Hurdle (Req g minus delivered) | +5.9 pp | +22.2 pp | 2nd least demanding of 6 |
| ROIC minus cost of capital | +5.6 pp | -7.7 pp | 2nd highest of 9 |
| EV / EBITDA | 15.0× | n/a | — |
| Net debt / EBITDA | -2.3× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.22B | +34% | +18% | 10% | 27.0× | 15.8% | +9.9% |
| Vor Biopharma VOR | United States | $1.22B | +17% | n/a | n/a | n/a | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.22B | -13% | n/a | n/a | n/a | n/a | n/a |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.23B | -60% | -5% | -181% | n/a | n/a | n/a |
| SpyGlass Pharma SGP | United States | $1.24B | +58% | n/a | n/a | n/a | n/a | n/a |
| UroGen Pharma URGN | United States | $1.21B | -16% | +159% | -12% | 13.9× | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.24B | -37% | -100% | n/a | n/a | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.17B | -36% | n/a | -838% | n/a | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.28B | -10% | -9% | 0% | 46.2× | 8.8% | -7.0% |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.14B | -10% | -24% | -2% | 31.0× | 16.4% | -5.8% |
| Daan Gene 002030.SZ | China | $1.11B | -9% | +1% | -81% | n/a | 5.7% | -32.3% |
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 29.4× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | n/a | n/a | n/a |
| Janux Therapeutics JANX | United States | $1.08B | +24% | +5,367% | -598% | n/a | n/a | n/a |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 8.6× | -1.2% | +25.6% |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 42.8× | 36.5% | -13.1% |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |